BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36179816)

  • 1. TGF-β at the crossroads of multiple prognosis in breast cancer, and beyond.
    Shukla N; Naik A; Moryani K; Soni M; Shah J; Dave H
    Life Sci; 2022 Dec; 310():121011. PubMed ID: 36179816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis.
    Imamura T; Hikita A; Inoue Y
    Breast Cancer; 2012 Apr; 19(2):118-24. PubMed ID: 22139728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
    Matise LA; Palmer TD; Ashby WJ; Nashabi A; Chytil A; Aakre M; Pickup MW; Gorska AE; Zijlstra A; Moses HL
    Breast Cancer Res; 2012 Jul; 14(4):R98. PubMed ID: 22748014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRRX2 as a novel TGF-β-induced factor enhances invasion and migration in mammary epithelial cell and correlates with poor prognosis in breast cancer.
    Juang YL; Jeng YM; Chen CL; Lien HC
    Mol Carcinog; 2016 Dec; 55(12):2247-2259. PubMed ID: 26824226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta.
    Sokol JP; Neil JR; Schiemann BJ; Schiemann WP
    Breast Cancer Res; 2005; 7(5):R844-53. PubMed ID: 16168131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Molecular Mechanism of Epithelial-Mesenchymal Transition for Breast Carcinogenesis.
    Li CJ; Chu PY; Yiang GT; Wu MY
    Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31514467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.
    Johansson J; Berg T; Kurzejamska E; Pang MF; Tabor V; Jansson M; Roswall P; Pietras K; Sund M; Religa P; Fuxe J
    Oncogene; 2013 Dec; 32(50):5614-24. PubMed ID: 23955085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
    Wendt MK; Smith JA; Schiemann WP
    Oncogene; 2010 Dec; 29(49):6485-98. PubMed ID: 20802523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.
    Allington TM; Schiemann WP
    Cells Tissues Organs; 2011; 193(1-2):98-113. PubMed ID: 21051857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: an update.
    Zu X; Zhang Q; Cao R; Liu J; Zhong J; Wen G; Cao D
    Cell Tissue Res; 2012 Jan; 347(1):73-84. PubMed ID: 21845401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models.
    Li Y; Drabsch Y; Pujuguet P; Ren J; van Laar T; Zhang L; van Dam H; Clément-Lacroix P; Ten Dijke P
    Breast Cancer Res; 2015 Feb; 17(1):28. PubMed ID: 25849225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) β: LncRNA-hit-mediated TGFβ-induced epithelial to mesenchymal transition in mammary epithelia.
    Richards EJ; Zhang G; Li ZP; Permuth-Wey J; Challa S; Li Y; Kong W; Dan S; Bui MM; Coppola D; Mao WM; Sellers TA; Cheng JQ
    J Biol Chem; 2015 Mar; 290(11):6857-67. PubMed ID: 25605728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism.
    Lee YH; Albig AR; Regner M; Schiemann BJ; Schiemann WP
    Carcinogenesis; 2008 Dec; 29(12):2243-51. PubMed ID: 18713838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis.
    Chen W; Zhou S; Mao L; Zhang H; Sun D; Zhang J; Li J; Tang JH
    Tumour Biol; 2016 Aug; 37(8):10011-9. PubMed ID: 27153853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterodimer formation by Oct4 and Smad3 differentially regulates epithelial-to-mesenchymal transition-associated factors in breast cancer progression.
    Mandal G; Biswas S; Roy Chowdhury S; Chatterjee A; Purohit S; Khamaru P; Chakraborty S; Mandal PK; Gupta A; de la Mare JA; Edkins AL; Bhattacharyya A
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2053-2066. PubMed ID: 29526821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
    Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
    Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression.
    Neil JR; Tian M; Schiemann WP
    J Biol Chem; 2009 Aug; 284(32):21209-17. PubMed ID: 19531477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
    Deckers M; van Dinther M; Buijs J; Que I; Löwik C; van der Pluijm G; ten Dijke P
    Cancer Res; 2006 Feb; 66(4):2202-9. PubMed ID: 16489022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells.
    Zhang J; Thorikay M; van der Zon G; van Dinther M; Ten Dijke P
    J Vis Exp; 2020 Oct; (164):. PubMed ID: 33191940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment.
    Tian H; Liu J; Chen J; Gatza ML; Blobe GC
    Oncogene; 2015 Nov; 34(45):5635-47. PubMed ID: 25823021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.